# US 2023/0413806 A1 · Enhancement of allograft quality by postmortem donor regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0413806 A1
- Document ID: US20230413806A1
- Status: Published application
- Kind: A1
- Application number: 18/339,135
- Filed: 2023-06-21
- Published: 2023-12-28
- Earliest claimed: 2022-06-23
- Assignees: Venvalo Group LLC
- Applicants: Venvalo Group LLC
- Inventors: Thomas E. ICHIM; Kalina O'CONNOR; Boris N. REZNIK
- Web page: https://patentgrep.com/patent/US20230413806A1

## CPC

- A01N 1/12: Chemical aspects of preservation
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- C12N 5/0645: {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2500/05: Inorganic components
- C12N 2501/113: Acidic fibroblast growth factor (aFGF, FGF-1)
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/231: Interleukin-10 (IL-10)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described are means, methods and compositions of matter useful for enhancing quality of organ transplants by induction of postmortem regeneration. The disclosure provides administration of regenerative cells and/or factors in a brain dead recipient whose body is maintained in a viable state by life supporting machinery.

## Claims

### Claim 1

A method of increasing the quality of organs for transplantation comprising the steps of:
a) obtaining a brain-dead patient;
b) maintaining viability of said brain dead patient by one or more life supporting technologies;
c) administering to said patient one or more regenerative cell populations and;
d) harvesting said organs.

### Claim 2 (depends on 1)

The method of claim 1, wherein said regenerative cell is a stem cell, including possibility a pluripotent stem cell or a mesenchymal stem cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein said pluripotent stem cells are selected from a group of cells comprising:
a) inducible pluripotent stem cells;
b) somatic cell nuclear transfer derived stem cells;
c) embryonic stem cells; and
d) parthenogenic derived stem cells.

### Claim 4 (depends on 2)

The method of claim 2, wherein said pluripotent stem cells are exposed to inflammatory stress before being provided to the brain dead patient.

### Claim 5 (depends on 4)

The method of claim 4, wherein said inflammatory stress is exposure to a toll-like receptor.

### Claim 6 (depends on 3)

The method of claim 3, wherein said inducible pluripotent stem cell possesses markers selected from a group comprising of: CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2, and HLA-A,B,C and possesses ability to undergo at least 40 doublings in culture, while maintaining a normal karyotype upon passaging.

### Claim 7 (depends on 6)

The method of claim 6, wherein said inducible pluripotent stem cells express OCT4.

### Claim 8 (depends on 3)

The method of claim 3, wherein said parthenogenic stem cells wherein said parthenogenically derived stem cells are generated by addition of a calcium flux inducing agent to activate an oocyte followed by enrichment of cells expressing markers selected from a group comprising of SSEA-4, TRA 1-60 and TRA 1-81.

### Claim 9 (depends on 3)

The method of claim 3, wherein said somatic cell nuclear transfer derived stem cells possess a phenotype negative for SSEA-1 and positive for SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, and alkaline phosphatase.

### Claim 10 (depends on 3)

The method of claim 3, wherein said mesenchymal stem cell are derived from tissue selected from the group consisting of a) Wharton's Jelly; b) bone marrow; c) peripheral blood; d) mobilized peripheral blood; e) endometrium; f) hair follicle; g) deciduous tooth; h) testicle; i) adipose tissue; j) skin; k) amniotic fluid; l) cord blood; m) omentum; n) muscle; o) amniotic membrane; o) periventricular fluid; and p) placental tissue.

### Claim 11 (depends on 10)

The method of claim 10, wherein said mesenchymal stem cells express a marker or plurality of markers selected from the group consisting of: STRO-1, CD90, CD73, CD105, CD54, CD106, HLA-I markers, vimentin, ASMA, collagen-1, fibronectin, LFA-3, ICAM-1, PECAM-1, P-selectin, L-selectin, CD49b/CD29, CD49c/CD29, CD49d/CD29, CD61, CD18, CD29, thrombomodulin, telomerase, CD10, CD13, STRO-2, VCAM-1, CD146, and THY-1.

### Claim 12 (depends on 11)

The method of claim 11, wherein said mesenchymal stem cells do not express substantial levels of HLA-DR, CD117, and CD45.

### Claim 13 (depends on 11)

The method of claim 11, wherein said mesenchymal stem cells express CD56.

### Claim 14 (depends on 11)

The method of claim 11, wherein said mesenchymal stem cell are activated by exposure to a toll like receptor agonist.

### Claim 15 (depends on 1)

The method of claim 1, wherein said regenerative cells are monocytes.

### Claim 16 (depends on 15)

The method of claim 15, wherein said regenerative cells are monocytes that have been treated with interleukin-10.

### Claim 17 (depends on 15)

The method of claim 15, wherein said regenerative cells are monocytes that have been exposed to hypoxia.

### Claim 18 (depends on 15)

The method of claim 15, wherein said regenerative cells are monocytes that have been exposed to HGF-1.

### Claim 19 (depends on 15)

The method of claim 15, wherein said regenerative cells are monocytes that have been exposed to FGF-1.

### Claim 20 (depends on 15)

The method of claim 15, wherein said regenerative cells are monocytes that have been exposed to krypton.
